title: Comparison of medical treatments in cryptogenic stroke patients with patent foramen ovale: A randomized clinical trial.
abstract: BACKGROUND
  This randomized clinical trial compared rates of stroke or transient ischemic attack recurrence or death in patients with cryptogenic stroke and patent foramen ovale (PFO) who received medical treatment with aspirin or warfarin.
  
  
  METHODS
  Forty-four Iranian patients with cryptogenic stroke and patent foramen ovale participated in this randomized, single-blind trial between July 2007 and June 2010. All patients underwent transesophageal echocardiography and contrast-transcranial Doppler sonography to confirm the presence of patent foramen ovale. The patients were randomly assigned to receive aspirin or warfarin and were followed for 18 months for the recurrence of ischemic events or death. The principal investigator was blind to the group assignment. This trial is registered under number IRCT138805192323N1.
  
  
  RESULTS
  Five (11.4%) patients had a stroke, 2 (4.5%) had a transient ischemic attack and 2 (4.5%) died. There was no difference in the rate of ischemic events or death between the aspirin- and warfarin-treated groups (hazard ratio: 0.45; 95% CI: 0.1-1.8; P = 0.259).
  
  
  CONCLUSIONS
  There was no difference in ischemic event recurrence, death rates or side-effects between patients with cryptogenic stroke and patent foramen ovale who were treated with aspirin vs. warfarin.
authors.affiliation: Department of Neurology, Shiraz Neurosciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Abdolhamid
authors.initials: A
authors.lastname: Shariat
authors.forename: Ehsan
authors.initials: E
authors.lastname: Yaghoubi
authors.forename: Mohsen
authors.initials: M
authors.lastname: Farazdaghi
authors.forename: Kamran
authors.initials: K
authors.lastname: Aghasadeghi
authors.forename: Afshin
authors.initials: A
authors.lastname: Borhani Haghighi
keywords: Aspirin; cryptogenic stroke; patent foramen ovale; warfarin
references.citation: Stroke. 1998 Jul;29(7):1322-8
references.pmid: 9660381
references.citation: J Clin Neurosci. 2011 Nov;18(11):1486-9
references.pmid: 21917461
references.citation: N Engl J Med. 2001 Dec 13;345(24):1740-6
references.pmid: 11742048
references.citation: Stroke. 2011 Oct;42(10):2891-5
references.pmid: 21817145
references.citation: Stroke. 2008 Dec;39(12):3131-6
references.pmid: 18818401
references.citation: Stroke. 2009 Jul;40(7):2349-55
references.pmid: 19443800
references.citation: Am J Cardiol. 2009 Jan 1;103(1):124-9
references.pmid: 19101242
references.citation: J Stroke Cerebrovasc Dis. 2012 Nov;21(8):662-6
references.pmid: 21459615
references.citation: Stroke. 2010 Jan;41(1):e3-e10
references.pmid: 19926844
references.citation: Stroke. 2011 Jan;42(1):227-76
references.pmid: 20966421
references.citation: Am J Med. 2000 Oct 15;109(6):456-62
references.pmid: 11042234
references.citation: Circulation. 2002 Jun 4;105(22):2625-31
references.pmid: 12045168
references.citation: N Engl J Med. 2007 Nov 29;357(22):2262-8
references.pmid: 18046029
references.citation: Stroke. 2007 Nov;38(11):2979-84
references.pmid: 17901381
references.citation: Pharmacol Rep. 2010 Jul-Aug;62(4):740-6
references.pmid: 20885015
references.citation: Neurology. 2000 Oct 24;55(8):1172-9
references.pmid: 11071496